0.00Open0.35Pre Close0 Volume3 Open Interest8.00Strike Price0.00Turnover352.29%IV162.17%PremiumSep 20, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.35Extrinsic Value100Contract SizeAmericanOptions Type0.2889Delta0.1182Gamma9.10Leverage Ratio-0.0205Theta0.0004Rho2.63Eff Leverage0.0028Vega
MEI Pharma Stock Discussion
NEWS
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma, Inc. reports positive results from the ongoing Phase 1b study of ME-344 in combination with bevacizumab for relapsed metastatic colorectal cancer. 25% of patients had no disease progression at Week 16, exceeding the threshold to add more patients. The combination was well-tolerated, leading to the...
$Gossamer Bio (GOSS.US)$ $Starry Group (STRY.US)$ $Helbiz (HLBZ.US)$ $MEI Pharma (MEIP.US)$ $Digital Brands Group (DBGI.US)$ $Cosmos Health (COSM.US)$ $COMSovereign (COMS.US)$ $Mirati Therapeutics (MRTX.US)$ $United Parcel Service (UPS.US)$ $Sumo Logic (SUMO.US)$
wherr is thr link for earnings
Tomorrow to the 🚀🌕
https://www.etfdailynews.com/2022/05/02/mei-pharma-inc-nasdaqmeip-sees-significant-increase-in-short-interest/
Finally
No comment yet